Coreg
Product Images NDC 68151-5051

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Coreg (NDC 68151-5051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carvedilol Phosphate Chemical Structure (Coreg Cr Spl Graphic 01)

Chemical structure diagram showing the active ingredient associated with COREG CR by Carilion Materials Management. The diagram includes molecular groups and notation indicating phosphate and hydrated components (H3PO4 and H2O).*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Coreg Cr Spl Graphic 02)

A line graph showing % Mortality over Months comparing treatments labeled Placebo and Carvedilol. The graph depicts two increasing curves with Carvedilol showing lower mortality than Placebo across the time span of 0 to 21 months. A P value of 0.0014 is noted near the lower left.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Coreg Cr Spl Graphic 03)

A forest plot chart depicting hazard ratios for various patient subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure levels, and spironolactone usage. Each subgroup's hazard ratio is represented with a point estimate and confidence intervals across a scale from 0.0 to 2.0, with a reference line at 1.0.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Coreg Cr Spl Graphic 04)

A Kaplan-Meier curve chart showing percent mortality over 24 months for two groups labeled placebo and carvedilol. The y-axis represents % mortality from 0 to 30%, and the x-axis represents time in months from 0 to 24. Text on the chart indicates a p-value of 0.03, suggesting a statistical comparison between the two groups.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Coreg Cr Spl Graphic 05)

A forest plot displaying hazard ratios for different patient subgroups following myocardial infarction (MI). It compares outcomes based on age, gender, timing post-MI, prior intravenous/oral beta-blocker use, Killip classification, thrombolytic therapy, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (CHF), diuretics use during MI, angina, hypertension, diabetes, heart rate, and systolic blood pressure (SBP). The x-axis shows hazard ratio values ranging approximately from 0.4 to 1.3.*

FDA Label Image

Figure 5. Changes From Baseline In Systolic Blood Pressure And Diastolic Blood Pressure Measured By 24-hour Abpm (Coreg Cr Spl Graphic 06)

Two line graphs showing change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of COREG CR at 20 mg, 40 mg, and 80 mg strengths. The graphs illustrate time-dependent blood pressure changes using smoothed regression lines.*

FDA Label Image

Label Image (Lbl681515051)

Label of COREG CR 80 mg extended-release capsules containing carvedilol phosphate. The label shows the manufacturer as GSK, batch number 3ZP2170, and expiration date 09/14. It includes an NDC barcode and the indication 'Rx only.' Labeler is Carilion Materials Management.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.